Comparison
Omega-3 (EPA/DHA) vs TB-500
Side-by-side of Omega-3 (EPA/DHA) and TB-500. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
Omega-3 (EPA/DHA)
Omega 3 fish oil profile: EPA/DHA marine fatty acids, 2-4 g/day cuts triglycerides 20-30%, REDUCE-IT showed 25% cardiovascular risk reduction on icosapent eth.
TB-500
TB-500 peptide, a 17-aa thymosin beta-4 fragment. Preclinical tendon and wound healing via actin sequestration. Typical dosage 2 to 5 mg weekly. No human RCTs.
Effects at a glance
Omega-3 (EPA/DHA)
- •Reduces fasting triglycerides 20-50% at 2-4 g/day in hypertriglyceridemic patients
- •REDUCE-IT showed 25% relative risk reduction in major CV events at 4 g/day icosapent ethyl
- •Modest antidepressant effect (SMD ~0.40) for EPA-dominant formulations at 1-2 g/day
- •Atrial fibrillation incidence rises ~30-50% at 4 g/day; relevant for older patients with pre-existing CV disease
- •Tissue omega-3 index (RBC EPA + DHA) target ~8%; Western baseline typically 4-5%
- •Triglyceride and re-esterified triglyceride forms absorb ~70% better than ethyl esters in fasted state
TB-500
- •17-amino-acid fragment of endogenous Thymosin Beta-4, an actin-sequestering peptide
- •Preclinical models show accelerated tendon, ligament, and dermal wound healing
- •Equine veterinary use for soft-tissue injury is the most documented real-world application
- •Anecdotal human protocols use 2 to 5 mg twice weekly subcutaneously for 4 to 6 weeks
- •WADA banned under S2 (peptide hormones, growth factors) since 2018
- •No completed phase II or III human RCTs as of 2026; long-term safety unestablished
Side-by-side
| Attribute | Omega-3 (EPA/DHA) | TB-500 |
|---|---|---|
| Category | supplement | peptide |
| Also known as | fish oil, EPA, DHA, marine omega-3 | Thymosin Beta-4 fragment, TB4-Frag, Thymosin Beta 4 |
| Half-life (hr) ↗ | 48 | 2 |
| Typical dose (mg) ↗ | 2000 | 2.5 |
| Dosing frequency | 1 to 2 times daily with food | 2x weekly (anecdotal protocols) |
| Routes | oral | subcutaneous, intramuscular |
| Onset (hr) | 4 | - |
| Peak (hr) | 12 | - |
| Molecular weight | 302.45 | 4963.4 |
| Molecular formula | C20H30O2 (EPA); C22H32O2 (DHA) | C212H350N56O78S |
| Mechanism | Substitutes arachidonic acid in membrane phospholipids, shifting eicosanoid production toward less-inflammatory 3-series prostaglandins and 5-series leukotrienes. Activates PPAR-alpha to lower hepatic VLDL/triglyceride synthesis. DHA modulates synaptic membrane fluidity and neuronal function. | Sequesters G-actin monomers, modulates cell migration and angiogenesis, and upregulates VEGF and myosin transcription. Promotes endothelial differentiation and stem-cell migration to injury sites in preclinical models. |
| Legal status | Dietary supplement; prescription forms (icosapent ethyl, omega-3 acid ethyl esters) for severe hypertriglyceridemia | Not FDA approved; research-use-only grey market; banned by WADA |
| WADA status | allowed | banned |
| DEA / Rx | Not scheduled | Not FDA approved; not scheduled; research-chemical status |
| Pregnancy | Recommended at 200 to 600 mg DHA/day for fetal development | Insufficient data |
| CAS | 10417-94-4 | 885340-08-9 |
| PubChem CID | 446284 | 62707662 |
| Wikidata | Q207688 | Q7799921 |
Safety profile
Omega-3 (EPA/DHA)
Common side effects
- fishy aftertaste
- eructation (fish burps)
- mild dyspepsia
- loose stools at high doses
Contraindications
- fish allergy (use algal omega-3 alternative)
- active bleeding disorders
- scheduled surgery (discontinue 5-7 days prior)
Interactions
- warfarin and DOACs: additive antiplatelet effect at 2+ g/day; meaningful bleeding risk(moderate)
- aspirin and antiplatelet agents: additive bleeding risk at high doses(moderate)
- statins: complementary cardiovascular effects; no pharmacokinetic interaction(minor)
- antiarrhythmics: high-dose omega-3 increases AF risk; relevant in pre-existing arrhythmia(moderate)
TB-500
Common side effects
- injection-site irritation
- fatigue (anecdotal)
- lethargy in early dosing (anecdotal)
Contraindications
- pregnancy
- active malignancy (theoretical angiogenic concern)
- no established human safety profile
Interactions
- BPC-157: Frequently co-administered in anecdotal healing protocols; no controlled interaction data(minor)
Which Should You Take?
Omega-3 (EPA/DHA) comes out ahead for most readers on the criteria we weight: 3 catalogued goals, OTC dietary supplement, oral dosing, with a Tier-A outcome catalogued. TB-500 is the right call when one of the conditionals below applies.
- → If your priority is cardiovascular health, pick Omega-3 (EPA/DHA).
- → If your priority is healthspan extension, pick Omega-3 (EPA/DHA).
- → If your priority is post-training recovery, pick TB-500.
- → If your priority is tendon repair, pick TB-500.
Edge case: If you want to avoid research-only / gray-market sourcing, Omega-3 (EPA/DHA) is the more accessible choice.
Default choice: Omega-3 (EPA/DHA). Lower friction to source, a Tier-A evidence outcome catalogued, and broader goal coverage. Reach for TB-500 only if your priority sits squarely in the goals it owns above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between Omega-3 (EPA/DHA) and TB-500?
Omega-3 (EPA/DHA) and TB-500 differ in category (supplement vs peptide), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, Omega-3 (EPA/DHA) or TB-500?
Omega-3 (EPA/DHA) half-life is 48 hours; TB-500 half-life is 2 hours.
Can you stack Omega-3 (EPA/DHA) with TB-500?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper